Gritstone bio, Inc.

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid t…

Biotechnology

US, EmeryVille [HQ]

Summary
IR
Fin. Reports
Financials
Leadership & Strategy
Possible Catalysts

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Financials

Analysts

Wall Street · Earnings · Institutional Sentiment

A comprehensive analysis section that covers unveiling insights about Gritstone bio, Inc.'s gradings, price targets and earnings estimates. None

Earnings
Grading & Price

Reported

Past Estimate Consensus

Future Estimate Consensus

Gritstone bio, Inc. can't present any analysts estimates at the moment detail analysis.